Author: Mark Newman

Share

Endocrine Society Advocacy in Action – June 2025

June2025Cover Administration Moves Forward with NIH Funding Cuts, Restructuring On Friday, May 2, the White House released the president’s budget request for Fiscal Year 2026 (FY26). As is typical in the first year of a presidential term, the budget lacks many details, and so it is informally referred to as a “skinny budget.” The budget outlines...
Share

Endocrine Society, Other Medical Organizations Issue Joint Statement on United States v. Skrmetti Decision

As experts dedicated to providing patients with compassionate, evidence-based care every day, we are disappointed in the United States v. Skrmetti decision, which increases the likelihood that other states will limit or eliminate families’ and patients’ ability to access medical care.   As doctors, nurse practitioners, and nurses, we believe that every patient is different. Decisions...
Share

Bright Minds. Bold City.

Endocrinology’s brightest minds will gather once again in San Francisco from July 12–15 for ENDO 2025. Showcasing groundbreaking research, cutting-edge clinical advances, and abstract discussions on the future of hormone science and care, our signature conference promises a transformative experience for researchers, clinicians, and healthcare leaders alike. While San Francisco sets the stage for ENDO...
Share

Pharma Fridays – June 13, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * MiniMed to be Metronic’s New Diabetes Company On June 12, Medtronic plc announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company’s roots, reflecting its original name prior to its acquisition by...
Share

AMA Passes Resolution Calling for Expanded Access to Anti-obesity Medications 

Endocrine Society champions resolution passed by House of Delegates On June 10, the American Medical Association (AMA) House of Delegates passed the Endocrine Society’s resolution to improve access to anti-obesity medications.  In the resolution, the AMA committed to advocating for reducing the burden of prior authorization, when healthcare providers must seek insurance plan approval before...
Share

Bypass and Beyond: Redefining Roles and Mechanisms of Obesity Treatment at ENDO 2025

Endocrine News talks with the chair and presenters of “Bariatric Surgery and Emerging Medications: Redefining Roles and Mechanisms,”an ENDO 2025 session that analyzes a variety of factors that are impacted by bariatric surgery including postsurgical hypoglycemia, surgery versus pharmacological solutions, as well as a number of molecular mechanisms of the surgery itself. With so many...
Share

Pharma Fridays – June 6, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist On June 2, Regeneron Pharmaceuticals, Inc., announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the...
Share

Endocrine Society Endorses Treat and Reduce Obesity Act

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.  The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law.  Access to these medications would benefit millions of Americans. More than...